DrugPatentWatch Database Preview

TREXIMET Drug Profile

  Purchase this report

or, see our see our flat-rate plans

« Back to Dashboard

When do Treximet patents expire, and what generic alternatives are available?

Treximet is a drug marketed by Pernix Ireland Ltd and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-three patent family members in sixteen countries.

The generic ingredient in TREXIMET is naproxen sodium; sumatriptan succinate. There are forty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the naproxen sodium; sumatriptan succinate profile page.

Summary for TREXIMET

International Patents:	33
US Patents:	5
Applicants:	1
NDAs:	1
Suppliers / Packagers:	4
Bulk Api Vendors:	1
Clinical Trials:	22
Formulation / Manufacturing:	see details
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TREXIMET
DailyMed Link:	TREXIMET at DailyMed

Pharmacology for TREXIMET

Ingredient-type	Nonsteroidal Anti-inflammatory Compounds
Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists Cyclooxygenase Inhibitors

US Patents and Regulatory Information for TREXIMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pernix Ireland Ltd	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-002	May 14, 2015		RX	Yes	No					Y
Pernix Ireland Ltd	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008	AB	RX	Yes	Yes
Pernix Ireland Ltd	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-002	May 14, 2015		RX	Yes	No
Pernix Ireland Ltd	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008	AB	RX	Yes	Yes

  Purchase this report

or, see our see our flat-rate plans

Expired US Patents for TREXIMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pernix Ireland Ltd	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008
Pernix Ireland Ltd	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008
Pernix Ireland Ltd	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-002	May 14, 2015
Pernix Ireland Ltd	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008

Paragraph IV (Patent) Challenges for TREXIMET

Drugname	Dosage	Strength	RLD	Submissiondate
	Tablets	500 mg/85 mg		2008-07-23

  Purchase this report

or, see our see our flat-rate plans

International Patents for TREXIMET

Country	Document Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9806392
Cyprus	1112640
Portugal	957914
Mexico	PA05006954

Supplementary Protection Certificates for TREXIMET

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
11/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
2012000051	Germany		PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
2011005,C0984957	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
2011005	Lithuania		PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126